Eric von Hofe, Ph.D. President Antigen Express, Inc. “How Technology Works and Update on Clinical Trials” at Biotech, Life Science, Healthcare Week 2013

Antigen Express Website: http://www.antigenexpress.com/

Generex Website: http://generex.com/

Antigen Express, Inc., a division of Generex Biotechnology (GNBT:OTCBB) is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The company’s focus is on stimulating critical members of the immune response, known as CD4+ T helper cells. The technology allows for antigen-specific stimulation or suppression of a T-helper response to virtually any antigen of known pathogenic potential. Using this technology, Antigen Express is building a deep pipeline of therapeutics aimed at a variety of major diseases, including cancer, infectious diseases and autoimmune-based syndromes. SNNLive caught up with Eric von Hofe, Ph.D., President of Antigen Express, Inc. at the 2013 Biotech, Life Science, Healthcare week in San Francisco, CA.

“What we are trying to do at Antigen Express is to expand the stimulation of the immune system such that rather than just stimulate the immune system just to recognize pathogens like flu…to recognize other pathogenic agents, in particular cancer,” he begins.  Dr. von Hofe goes to explain how the Antigen Express technology works, “they [Antigen Express Platform technology] modify tumor-associted antigens so they enable the immune system to recognize cancer cells as though they were a foreign agent, and this is always been the big problem in treating cancer with immunotherapy. Obviously, cancer arises as normal tissue from your body so the immune system doesn’t really like to go after normal tissue. We found a way of essentially taking these tumor-associated antigens and making them visible to the immune system so the immune system can then attack cancer cells at periods long time after the immunotherapy has been given to the patient.”

“We were perfectly positioned with our technology, a way of making tumor antigens visible to the immune system, that we initiated clinical trials in 2005. This year the big event is that we have submitted our interim data to the FDA, so this is the largest Phase 2 trial done with a cancer vaccine; controlled, randomized trial, and on the basis of those data submitted to the FDA, they’ve essentially green-lighted us to go ahead and submit a proposal for the protocol for the Phase 3″, he goes on to explain. For more information about Antigen Express, Inc., check out their website. SNNLive welcomes back Eric von Hofe, Ph.D., President of Antigen Express, Inc.

View the full GNBT chart at Wikinvest